found that compared to mutation status, the P53 deficiency gene signature derived from the integration of gene expression accurately predicted drug sensitivity and overall survival (OS) in BC; we considered this as the benchmark for comparison with our results in this study [22]. The gene discussed is TP53; the disease is breast cancer.